Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.03
+0.02000.12%
Post-market: 17.030.00000.00%16:10 EDT
Volume:332.38K
Turnover:5.66M
Market Cap:882.64M
PE:16.30
High:17.07
Open:17.02
Low:17.00
Close:17.01
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.78M
Volume Ratio:0.89
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.05
PE(LYR):8.27

Loading ...

May 15, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 10, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 08, 2023

Major Issues Report

8-K - Current report
May 03, 2023

Major Issues Report

8-K - Current report
Apr 17, 2023

Major Issues Report

8-K - Current report
Apr 14, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
Apr 12, 2023

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Apr 11, 2023

Major Issues Report

8-K - Current report
Mar 13, 2023

Major Issues Report

8-K - Current report
Mar 01, 2023

Major Issues Report

8-K/A [Amend] - Current report
Mar 01, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 28, 2023

Major Issues Report

8-K - Current report
Feb 27, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 13, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 09, 2023

Major Issues Report

8-K - Current report
Dec 12, 2022

Major Issues Report

8-K - Current report